SCHEMBL3013025

SCHEMBL3013025

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.39
RAB9A P51151 2/20 0.39
GBA1 P04062 1/20 0.38
POLB P06746 3/20 0.36
MAPT P10636 3/20 0.36
TP53 P04637 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KDM1A O60341 1/20 0.36
NPC1 O15118 1/20 0.36
HTR6 P50406 1/20 0.35
PGR P06401 1/20 0.35
HTR2A P28223 1/20 0.35
DNM1L O00429 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003047 0.93 RAB9A (0.41) SMN1; SMN2RAB9APOLBMAPTALDH1A1
SCHEMBL3264261 0.93 RAB9A (0.39) SMN1; SMN2RAB9APOLBMAPTKMT2A
SCHEMBL3013358 0.93 RAB9A (0.39) SMN1; SMN2RAB9AGBA1POLBMAPT
SCHEMBL3003648 0.92 SMN1; SMN2 (0.38) SMN1; SMN2RAB9AGBA1POLBMAPT
SCHEMBL3018787 0.92 RAB9A (0.39) SMN1; SMN2RAB9AGBA1POLBMAPT
SCHEMBL3013512 0.92 HTR2A (0.44) SMN1; SMN2RAB9AMAPTALDH1A1KMT2A
SCHEMBL3017660 0.91 RAB9A (0.38) SMN1; SMN2RAB9APOLBMAPTTP53
SCHEMBL3016036 0.91 RAB9A (0.38) SMN1; SMN2RAB9APOLBMAPTNPC1
SCHEMBL3013306 0.91 RAB9A (0.42) SMN1; SMN2RAB9APOLBMAPTALDH1A1
SCHEMBL3010954 0.90 KCNQ1 (0.42) SMN1; SMN2RAB9AMAPTTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885GBA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.